Vascular Biogenics Ltd. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (29)

Latest Posts

About This Stock More About This Stock
Vascular Biogenics Ltd. Shares Climb Up On Positive Phase 3 Note
Article By: TickerTV
Friday, April 21, 2017 11:43 AM EDT
VBLT opened trading yesterday at $5.15 which was down from the previous day’s trading close of $5.20. VBLT closed trading yesterday at $5.20 and spiked up after market to $6.05, equivalent to a 16% increase from the closing price.
In this article: VBLT
Read
Provectus Biopharmaceuticals Concludes FDA Meeting For PV-10 Phase 3; Successful Completion Of AB Science's Futility Test For Masitinib
Article By: BioMedReports
Tuesday, February 10, 2015 5:59 AM EDT
Here is a look at some of the headlines for companies that made news in the healthcare sector on February 9, 2015.
In this article: ACHN, AKBS, AKR.L, AVXL, BIOC, BMRN, BSDM, CLDX, CBMG, CEMI, ENSG, GALE, ICUI, ISLT, IART, JUNO, LJPC, LFVN, MJNA, HTGC, NSPH, OREX, RDHL.TA, RCPT, RGLS, RNN, SBRA, WMGI, VBLT
Read
CERS Reports US Phase 2 Clinical Trial Of INTERCEPT Met Primary Endpoint; VBLT Announces Positive Phase 2a Data For VB-111
Article By: BioMedReports
Tuesday, December 23, 2014 8:18 AM EDT
CERS announced its Phase 2 clinical trial of red blood cells treated with the INTERCEPT Blood System. VBLT announced positive results from its exploratory Phase 2a study of VB-11.
In this article: CERS, VBLT
Read

Latest Tweets for $VBLT

No tweets yet!